Page last updated: 2024-10-29

2-propanol and Neovascularization, Optic Disc

2-propanol has been researched along with Neovascularization, Optic Disc in 27 studies

2-Propanol: An isomer of 1-PROPANOL. It is a colorless liquid having disinfectant properties. It is used in the manufacture of acetone and its derivatives and as a solvent. Topically, it is used as an antiseptic.
propan-2-ol : A secondary alcohol that is propane in which one of the hydrogens attached to the central carbon is substituted by a hydroxy group.

Research Excerpts

Excerpt	Relevance	Reference
"Retinal hemangioblastoma is one of the most common tumors in von Hippel-Lindau disease."	1.42	Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: a case report. ( Chan, CC; Chen, S; Chew, EY, 2015)

Research

Studies (27)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (3.70)	18.7374
1990's	10 (37.04)	18.2507
2000's	11 (40.74)	29.6817
2010's	5 (18.52)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, S	1
Chew, EY	1
Chan, CC	1
Limpas, Y	1
Rodarie, C	1
Wary, P	1
Gulkilik, G	1
Erdenoz, S	1
Oba, EM	1
Chan, CK	1
Ip, MS	1
Vanveldhuisen, PC	1
Oden, NL	1
Scott, IU	1
Tolentino, MJ	1
Blodi, BA	1
Deák, GG	1
Bolz, M	1
Prager, S	1
Ritter, M	1
Kriechbaum, K	1
Scholda, C	2
Schmidt-Erfurth, U	1
Ababneh, OH	1
Yousef, YA	1
Gharaibeh, AM	1
Abu Ameerh, MA	1
Abu-Yaghi, NE	1
Al Bdour, MD	1
Lang, GE	1
Thumann, G	1
Kirchhof, B	2
Lavie, G	1
Mandel, M	1
Hazan, S	1
Barliya, T	1
Blank, M	1
Grunbaum, A	1
Meruelo, D	1
Solomon, A	1
Avery, RL	2
Pearlman, J	1
Pieramici, DJ	1
Rabena, MD	1
Castellarin, AA	1
Nasir, MA	1
Giust, MJ	1
Wendel, R	1
Patel, A	1
Dorrell, M	1
Uusitalo-Jarvinen, H	1
Aguilar, E	1
Friedlander, M	1
Stout, JT	1
Batioğlu, F	1
Astam, N	1
Ozmert, E	1
Meyer-Schwickerath, R	2
Hagel, A	1
Nahberger, D	2
Gronemeyer, U	2
Haddad, R	1
Nagel, G	1
Egger, S	1
Abadi, A	1
Atamniy, J	1
Niehaus, H	1
Kroll, P	1
Lee, BL	1
Bateman, JB	1
Schwartz, SD	1
Uram, M	1
Bourke, RD	1
Cooling, RJ	1
Greven, CM	1
Hackel, RE	1
Slusher, MM	1
Saygili, O	1
Hamanaka, T	1
Akabane, N	1
Yajima, T	1
Takahashi, T	1
Tanabe, A	1
Lim, JI	1
Bressler, NM	1
Hayreh, SS	1
Klugman, MR	1
Podhajsky, P	1
Servais, GE	1
Perkins, ES	1
Capone, A	1
Meredith, TA	1
Lemmen, KD	1
Moter, H	1
Heimann, K	1

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide With Standard Care to Treat Macular Edema[NCT00105027]	Phase 3	682 participants (Actual)	Interventional	2004-10-31	Completed
Morphological and Functional Retinal Changes Following Retinal Photocoagulation Using a Semiautomated Patterned Scanning Laser System in Proliferative Retinopathy or Macular Edema Secondary to Diabetes Mellitus or Retinal Vein Occlusion[NCT00682240]	Phase 4	64 participants (Actual)	Interventional	2007-10-31	Completed
Intravitreal Bevacizumab Vs Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A One-Year Prospective, Contralateral Eye Study[NCT00347698]	Phase 2/Phase 3	30 participants	Interventional	2006-03-31	Recruiting
A Phase I Study to Evaluate the Ocular and Non Ocular Safety of Ranibizumab in Treating Neovascularization Secondary to Sickle Cell Retinopathy[NCT00618644]		0 participants (Actual)	Interventional	2010-01-31	Withdrawn (stopped due to Withdrawn due to lack of eligible participants)
Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography[NCT03246152]	Phase 4	31 participants (Actual)	Interventional	2017-10-23	Completed
Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma[NCT00727038]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2008-01-04	Withdrawn (stopped due to Company withdrew funding/sponsorship)
Histologic Changes of Fibrovascular Membrane Associated With Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab (Avastin®)[NCT00423059]		20 participants	Interventional	2006-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Changes From Baseline in Best-corrected ETDRS Visual Acuity Score

(NCT00105027)
Timeframe: 12 months

Intervention	letters read (Mean)
CRVO Observation	-12.1
CRVO 1 mg Dose Triamcinolone Acetonide	-1.2
CRVO 4 mg Dose Triamcinolone Acetonide	-1.2
BRVO Standard Care	4.2
BRVO 1 mg Dose Triamcinolone Acetonide	5.7
BRVO 4 mg Dose Triamcinolone Acetonide	4.0

Changes in Retinal Thickness as Assessed by Stereoscopic Color Fundus Photography and Optical Coherence Tomography

(NCT00105027)
Timeframe: 12 months

Intervention	um (Median)
CRVO Observation	-277
CRVO 1 mg Dose Triamcinolone Acetonide	-196
CRVO 4 mg Dose Triamcinolone Acetonide	-261
BRVO Standard Care	-224
BRVO 1 mg Dose Triamcinolone Acetonide	-149
BRVO 4 mg Dose Triamcinolone Acetonide	-170

The Number of Study Participants Experiencing an Improvement by 15 or More Letters From Baseline in Best-corrected ETDRS Visual Acuity Score at the 12-month Visit

Visual acuity testing was done using electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity testing at 3 meters using the Electronic Visual Acuity Tester by a SCORE certified technician. A masked visual acuity examiner with no knowledge of treatment assignments performed visual acuity testing at the 4-month, 12-month, 24-month and 36-month visits. An E-ETDRS visual acuity score of 85 is approximately 20/20, and a score of 20 letters is approximately 20/400. A visual acuity letter score change of 15 is about three lines on a vision chart. (NCT00105027)
Timeframe: Change from baseline to 12 months

Intervention	Participants (Number)
CRVO Observation	5
CRVO 1 mg Dose Triamcinolone Acetonide	22
CRVO 4 mg Dose Triamcinolone Acetonide	21
BRVO Standard Care	35
BRVO 1 mg Dose Triamcinolone Acetonide	31
BRVO 4 mg Dose Triamcinolone Acetonide	34

Adverse Ocular Outcomes

(NCT00105027)
Timeframe: 12 months

,,,,,

Intervention	events (Number)
	Initiation of IOP-lowering medications	IOP > 35 mm HG	IOP > 10 mm HG above baseline	Laser peripheral iridotomy	Trabeculectomy	Tube shunt	Cataract: lens opacity onset or progression	Cataract surgery	Infectious endophthalmitis	Noninfectious endophthalmitis	Retinal detachment	Iris neovascularization	Retinal neovascularization	Vitreous hemorrhage	YAG capsulotomy	Sector or panretinal photocagulation	Pars plana vitrectomy
BRVO 1 mg Dose Triamcinolone Acetonide	11	2	12	0	0	0	27	0	0	0	1	1	1	1	0	1	0
BRVO 4 mg Dose Triamcinolone Acetonide	57	14	50	1	0	0	38	4	1	0	0	2	3	3	1	4	1
BRVO Standard Care	3	1	1	0	0	0	15	3	0	0	1	1	5	2	1	5	1
CRVO 1 mg Dose Triamcinolone Acetonide	18	5	15	0	0	2	20	0	0	0	0	9	2	4	0	9	2
CRVO 4 mg Dose Triamcinolone Acetonide	32	8	24	1	0	0	25	4	0	0	0	4	2	0	0	3	0
CRVO Observation	7	1	2	0	0	0	12	0	0	0	0	2	4	4	1	5	1

BCVA Change

Correlation of BCVA change with degree of capillary non-perfusion before and after injections (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.

Intervention	Logmar (Mean)
Bevacizumab Group	-0.21

FAZ Area Change

Effect of repeated intravitreal Anti-VEGF injections on Foveal Avascular Zone (FAZ) area measured using the freehand tool of ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.

Intervention	mm^2 (Mean)
Bevacizumab Group	0.03

Macular Capillary Density Change at Full Retinal Thickness

Effect of repeated intravitreal Anti-VEGF injections on macular capillary density using the change in the skeletonized vascular density and fractal dimension measured by ImageJ (NCT03246152)
Timeframe: At baseline and after 3-6 consecutive monthly injections.

Intervention	percentage of vascularity (Mean)
Bevacizumab Group	-2.5

Reviews

1 review available for 2-propanol and Neovascularization, Optic Disc

Article	Year
Ocular neovascularization: basic mechanisms and therapeutic advances. Survey of ophthalmology, 2007, Volume: 52 Suppl 1 Topics: Angiogenesis Inhibitors; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Iris; Neova	2007

Trials

3 trials available for 2-propanol and Neovascularization, Optic Disc

Article	Year
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology, 2011, Volume: 118, Issue:7 Topics: Aged; Capillaries; Female; Glaucoma, Neovascular; Glucocorticoids; Humans; Incidence; Iris; Ischemia	2011
Photoreceptor layer regeneration is detectable in the human retina imaged by SD-OCT after laser treatment using subthreshold laser power. Investigative ophthalmology & visual science, 2012, Volume: 53, Issue:11 Topics: Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Iri	2012
Argon laser panretinal photocoagulation in ischemic central retinal vein occlusion. A 10-year prospective study. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1990, Volume: 228, Issue:4 Topics: Aged; Analysis of Variance; Clinical Protocols; Data Interpretation, Statistical; Female; Glaucoma,	1990

Other Studies

23 other studies available for 2-propanol and Neovascularization, Optic Disc

Article	Year
Pathology characteristics of ocular von Hippel-Lindau disease with neovascularization of the iris and cornea: a case report. Journal of medical case reports, 2015, Mar-25, Volume: 9 Topics: Adult; Cornea; Corneal Perforation; Hemangioblastoma; Humans; Iris; Male; Retinal Neoplasms; Retinal	2015
[Anterior segment examination of a post-traumatic, multioperated eye with Visante OCT. A case report]. Journal francais d'ophtalmologie, 2009, Volume: 32, Issue:9 Topics: Adult; Ciliary Body; Epiretinal Membrane; Eye Foreign Bodies; Eye Injuries, Penetrating; Fibrosis; H	2009
A case of Joubert syndrome with features of ocular neovascularization. Journal of pediatric ophthalmology and strabismus, 2010, May-21, Volume: 47 Online Topics: Abnormalities, Multiple; Cerebellar Diseases; Cerebellum; Child; Electroretinography; Evoked Potenti	2010
Intravitreal bevacizumab in the treatment of diabetic ocular neovascularization. Retina (Philadelphia, Pa.), 2013, Volume: 33, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu	2013
[Steroid therapy of oedematous and neovascular eye diseases]. Klinische Monatsblatter fur Augenheilkunde, 2003, Volume: 220, Issue:6 Topics: Anti-Inflammatory Agents; Glucocorticoids; Humans; Injections; Iris; Macular Edema; Neovascularizati	2003
[Transplantation of iris pigment epithelium]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2004, Volume: 101, Issue:9 Topics: Aged; Animals; Cell Differentiation; Female; Follow-Up Studies; Fundus Oculi; Humans; Iris; Macular	2004
Anti-angiogenic activities of hypericin in vivo: potential for ophthalmologic applications. Angiogenesis, 2005, Volume: 8, Issue:1 Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Anthracenes; Cornea; Corneal Neovasc	2005
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina (Philadelphia, Pa.), 2006, Volume: 26, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diabetic Retinopathy; Female	2006
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology, 2006, Volume: 113, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclo	2006
Gene transfer for the treatment of neovascular ocular disease (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society, 2006, Volume: 104 Topics: Angiogenesis Inhibitors; Animals; Choroid; Corneal Neovascularization; Disease Models, Animal; Elect	2006
Rapid improvement of retinal and iris neovascularization after a single intravitreal bevacizumab injection in a patient with central retinal vein occlusion and neovascular glaucoma. International ophthalmology, 2008, Volume: 28, Issue:1 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Flu	2008
[Ischemic or non-ischemic central artery occlusion. An explanation for the development or lack of development of neovascularization]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 1994, Volume: 91, Issue:3 Topics: Blood Flow Velocity; Carotid Artery, Internal; Carotid Stenosis; Fluorescein Angiography; Humans; In	1994
[Postoperative leakage of silicone oil into the anterior chamber]. Klinische Monatsblatter fur Augenheilkunde, 1994, Volume: 204, Issue:4 Topics: Anterior Chamber; Cataract Extraction; Humans; Intraocular Pressure; Iris; Lenses, Intraocular; Opht	1994
[Pupillary dilatation with Eckardt iris retraction sutures within the scope of vitreoretinal surgery. A follow-up study]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 1993, Volume: 90, Issue:5 Topics: Diabetic Retinopathy; Follow-Up Studies; Humans; Iris; Mydriatics; Postoperative Complications; Prem	1993
Posterior segment neovascularization associated with optic nerve aplasia. American journal of ophthalmology, 1996, Volume: 122, Issue:1 Topics: Coloboma; Electroretinography; Female; Humans; Infant; Iris; Male; Microphthalmos; Optic Disk; Optic	1996
Endoscopic fluorescein angiography. Ophthalmic surgery and lasers, 1996, Volume: 27, Issue:10 Topics: Choroid Diseases; Endoscopy; Fluorescein; Fluorescein Angiography; Fluoresceins; Fluorescent Dyes; F	1996
Case of rubeosis in association with proliferative vitreoretinopathy (PVR) Retina (Philadelphia, Pa.), 1997, Volume: 17, Issue:3 Topics: Fluorescein Angiography; Fundus Oculi; Glaucoma, Neovascular; Humans; Iris; Laser Coagulation; Neova	1997
Capillary nonperfusion of the retina in diabetes mellitus. Archives of ophthalmology (Chicago, Ill. : 1960), 1998, Volume: 116, Issue:9 Topics: Adult; Capillaries; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Fluorescein Angiography; Humans	1998
[Development of neovascularization of the optic papilla, retina and iris. Dependence on site and extent of retinal ischemia]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2000, Volume: 97, Issue:6 Topics: Diabetic Retinopathy; Fluorescein Angiography; Humans; Iris; Ischemia; Neovascularization, Pathologi	2000
Retinal ischemia and angle neovascularization in proliferative diabetic retinopathy. American journal of ophthalmology, 2001, Volume: 132, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Diabetic Retinopathy; Female; Fluorescein A	2001
Atypical parafoveal telangiectasis with subsequent anterior and posterior segment neovascularization. Retina (Philadelphia, Pa.), 1992, Volume: 12, Issue:4 Topics: Fluorescein Angiography; Fovea Centralis; Fundus Oculi; Humans; Iris; Laser Coagulation; Male; Middl	1992
Profound central visual loss and ocular neovascularization in idiopathic recurrent branch retinal arterial occlusion. Retina (Philadelphia, Pa.), 1990, Volume: 10, Issue:4 Topics: Aged; Blindness; Glaucoma; Humans; Iris; Male; Neovascularization, Pathologic; Optic Disk; Recurrenc	1990
[Keratopathy following vitrectomy with silicone oil injection]. Fortschritte der Ophthalmologie : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 1989, Volume: 86, Issue:6 Topics: Cornea; Corneal Diseases; Diabetic Retinopathy; Endothelium, Corneal; Humans; Iris; Postoperative Co	1989